KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

AbCellera Biologics (ABCL) Cost of Revenue: 2020-2023

Historic Cost of Revenue for AbCellera Biologics (ABCL) over the last 4 years, with Dec 2023 value amounting to $3.1 million.

  • AbCellera Biologics' Cost of Revenue rose 101.82% to $3.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was $14.2 million, marking a year-over-year decrease of 78.65%. This contributed to the annual value of $12.8 million for FY2024, which is 9.88% down from last year.
  • AbCellera Biologics' Cost of Revenue amounted to $3.1 million in Q4 2023, which was down 10.61% from $3.5 million recorded in Q3 2023.
  • AbCellera Biologics' Cost of Revenue's 5-year high stood at $44.6 million during Q1 2022, with a 5-year trough of $437,000 in Q1 2020.
  • Moreover, its 3-year median value for Cost of Revenue was $3.8 million (2023), whereas its average is $10.6 million.
  • Its Cost of Revenue has fluctuated over the past 5 years, first spiked by 4,478.95% in 2021, then tumbled by 92.98% in 2022.
  • AbCellera Biologics' Cost of Revenue (Quarterly) stood at $25.5 million in 2020, then declined by 14.25% to $21.9 million in 2021, then tumbled by 92.98% to $1.5 million in 2022, then surged by 101.82% to $3.1 million in 2023.
  • Its Cost of Revenue stands at $3.1 million for Q4 2023, versus $3.5 million for Q3 2023 and $3.8 million for Q2 2023.